Navigation Links
Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Date:8/8/2008

physiologic

prandial (mealtime) insulin release and activity than Humulin R or

Humalog alone. Statistically significant pharmacokinetic (PK) and

glucodynamic (GD) improvements observed in the study include:

Significantly faster systemic absorption of each insulin starting with

the first observation time point of three minutes after injection,

faster and greater glucose lowering activity early after injection,

greater peak insulin levels for the same dose administered, lower

variability of key PK and GD variables across subjects, and improvement

for rHuPH20 in combination with Humulin across all parameters when

compared to Humalog alone.

-- Release of Chemophase(R) Phase I/IIa clinical results from a continuing

clinical trial in the treatment of superficial bladder cancer. Based

on the results, the Chemophase combination treatment of mitomycin plus

the rHuPH20 enzyme was well tolerated and appears safe. The study

reported no dose-limiting toxicities and no observed side effects

attributable to the enzyme, and established the dose for subsequent

clinical trials, therefore achieving the pre-defined primary objective

of the study. In addition, there were no neutralizing antibodies to

rHuPH20 detected and the plasma concentration of mitomycin was either

non-measureable or negligible and well below the threshold that may be

predictive for myelosuppression (a decrease in bone marrow activity,

resulting in fewer red blood cells, white blood cells, and platelets).

-- New findings of positive pre-clinical animal efficacy data for

pegylated-rHuPH20 enzyme (PEGPH20) at the American Association for

Cancer Research (AACR) Translational Cancer Medicine meeting in

Monterey, CA. The study showed that treatment of hormone resistant

human prostat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
2. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
3. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
8. Halozyme Therapeutics Amends Stockholder Rights Plan
9. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
10. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
11. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 RENU 28, the world's first ... available for purchase in Australia and New Zealand in ... beginning September 16th. The tour will make stops in Brisbane ... on the 18th, Sydney on the 20th, and Melbourne on ... and New Zealand and to educate people about the new ...
(Date:9/15/2014)... Cancer Immunotherapy Market : ... Therapies is a new market research report announced ... principal types of therapeutics that have become the ... immunotherapy (which is often called "immuno-oncology") in recent ... cellular immunotherapy. , The regular use of ...
(Date:9/15/2014)... from North Carolina State University have developed a technique ... applying very low voltages, opening the door to a ... technologies. The technique hinges on the fact that the ... deposited or removed acts as a surfactant, lowering ... fluid. , The researchers used a liquid metal alloy ...
(Date:9/15/2014)... researchers led by Northeastern University has developed a ... and a variety of nanocarbon structures in carbon ... scalable, which will allow the researchers to tailor ... in applications ranging from electronic devices to CNT-reinforced ... sports equipment. , Their findings were published in ...
Breaking Biology Technology:Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Researchers control surface tension to manipulate liquid metals 2Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... recent salmonella outbreaks in the United States: ground turkey; ... the list goes on, according to the U.S. Centers ... long, thanks to a promising new biosensor nanotechnology that ... food or animals reach the marketplace. In the AIP,s ...
... Life Technologies Corporation (NASDAQ: LIFE ) today ... Non-GAAP revenue for the third quarter was $929 million, an ... the third quarter of 2010. Excluding the impact of currency, ... the same period of the prior year. (Logo: ...
... SAN DIEGO, Oct. 25, 2011 Conatus Pharmaceuticals Inc. announced ... CTS-1027 in HCV patients.  This decision follows reports of laboratory ... participants. The top priority of Conatus is patient ... this study.  Conatus is conducting a thorough review of the ...
Cached Biology Technology:Life Technologies Announces Third Quarter 2011 Results 2Life Technologies Announces Third Quarter 2011 Results 3Life Technologies Announces Third Quarter 2011 Results 4Life Technologies Announces Third Quarter 2011 Results 5Life Technologies Announces Third Quarter 2011 Results 6Life Technologies Announces Third Quarter 2011 Results 7Life Technologies Announces Third Quarter 2011 Results 8Life Technologies Announces Third Quarter 2011 Results 9Life Technologies Announces Third Quarter 2011 Results 10Life Technologies Announces Third Quarter 2011 Results 11Life Technologies Announces Third Quarter 2011 Results 12Life Technologies Announces Third Quarter 2011 Results 13Life Technologies Announces Third Quarter 2011 Results 14Life Technologies Announces Third Quarter 2011 Results 15Life Technologies Announces Third Quarter 2011 Results 16Life Technologies Announces Third Quarter 2011 Results 17
(Date:9/16/2014)... LINCOLNSHIRE, Ill. , Sept. 16, 2014 ... asked to make important decisions about their 2015 benefits. ... retirement and health solutions business of Aon ... expected to take a more proactive role in managing ... more important than ever for individuals to understand how ...
(Date:9/15/2014)... study indicates that lowland tapir populations may continue to ... Researchers from the Office National de la Chasse ... San Diego Zoo Global reviewed data retrieved from camera ... four years and compared this data to current harvest ... on hunting tapirs in French Guiana," said Matthias Tobler, ...
(Date:9/15/2014)... vital source of energy for both plants and animals ... into the cell could lead to the design of ... the amount of fruits and vegetables farmers are able ... of these "pathways" into the cell by piecing together ... of spider silk. , To determine the size, shape ...
Breaking Biology News(10 mins):Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 3Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 4Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 5Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 6Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 7X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3
... cells called macrophages may be a source of inflammatory ... the most common and effective treatment for prostate cancer, ... University of California, San Diego (UCSD) School of Medicine. ... for the physiological function and growth of the prostate ...
... Groundbreaking research published today could revolutionise the way drugs ... sector, say its authors. , The University of Manchester ... unique insight into the working of enzymes ?biological molecules ... When these chemical reactions go wrong they can lead ...
... new University of Colorado at Boulder study shows that ... have more impaired thinking and memory skills than they ... 24 hours. , The study showed test subjects had ... the groggy period upon awakening known as sleep inertia, ...
Cached Biology News:Macrophage signaling may affect hormone resistance in prostate tumors 2Research could lead to better drugs and whiter whites 2Morning grogginess more debilitating than sleep deprivation, according to CU-Boulder study 2Morning grogginess more debilitating than sleep deprivation, according to CU-Boulder study 3
... Fully automated microarray slide processing offering ... The trend to miniaturization, automation and ... a powerful tool with many applications ... These applications range from gene expression ...
... The user-friendly Eppendorf Thermomixer R offers ... that require shaking, heating, and cooling. ... expanded its application and temperature control ... each accommodate 24 micro test tubes, ...
... DetectorTM Microarray Dot Blot Kits overcome this ... quantitation over a wide range in low-density ... detection. They are ideal for performing ... of samples for the presence of low ...
... is a high quality microarray scanner based on ... rejection and spatial resolution. The DNAscope LM ... cost microarray scanner that is upgradeable to a ... Features: Includes control module (computer), ...
Biology Products: